Ii-Key/HER-2/neu(776–790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors

By Sotiriadou Nectaria   Kallinteris Nikoletta   Gritzapis Angelos   Voutsas Ioannis   Papamichail Michael   Hofe Eric   Humphreys Robert   Pavlis Theodoros   Perez Sonia   Baxevanis Constantin  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 5, 2007-05 ,pp. : 601-613

Springer Publishing Company

Access to resources Recommend Favorite

Her-2/neu as Predictive Marker for Endocrine Therapy and Chemotherapy in Patients with Metastatic Breast Cancer

By Köstler Wolfgang J.   Zielinski Christoph C.  

Breast Cancer Research and Treatment, Vol. 81, Iss. 1, 2003-01 ,pp. : 73-84

Springer Publishing Company

Access to resources Recommend Favorite

Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer

By Gillogly Michael   Kallinteris Nikoletta   Xu Minzhen   Gulfo Joseph   Humphreys Robert   Murray James  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 6, 2004-06 ,pp. : 490-496

Springer Publishing Company

Access to resources Recommend Favorite

Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy

By Baxevanis Constantin   Sotiropoulou Panagiota   Sotiriadou Nectaria   Papamichail Michael  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 3, 2004-03 ,pp. : 166-175

Springer Publishing Company

Access to resources Recommend Favorite

HER-2/ neu Gene Amplification in Esophageal Adenocarcinoma and Its Influence on Survival

By Thompson Sarah  

Annals of Surgical Oncology, Vol. 18, Iss. 7, 2011-07 ,pp. : 2010-2017

Springer Publishing Company

Access to resources Recommend Favorite